Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

ee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Craig Johnson David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x118 212-845-4271

cjohnson@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact: Investor Contact:

Rhonda Chiger John Baldissera

Rx Communications BPC Financial Marketing

917-322-2569 800-368-1217

rchiger@rxir.com

(Tables Follow)

TorreyPines Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

December
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... Fertilizer Industry” is a professional and in-depth ... The report provides basic Seaweed Fertilizer information, ... industry chain structure as well as industry ... analysis, including domestic market as well as ...
(Date:8/21/2014)... 21, 2014 His Majesty Willem-Alexander, King ... The Court of His Majesty Willem-Alexander, King of the ... Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ... , The King will take part in the Grand ... for 11 a.m.-12:20 p.m. and tour the plant. POET-DSM ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
... Accera Inc., a privately,held biotechnology company focused on ... it has appointed William,T. Poncy, M.B.A., as vice ... commercial launch of Ketasyn (AC-1202) as a medical ... Alzheimer,s disease. "Given his strong track record ...
... Assay Development, Biomarker Identification ... and ADME/Tox Applications, ... MCET), entered into a worldwide,exclusive license and technology purchase agreement ... human liver cell lines. Corning paid MultiCell a license ...
... Alliance, the leading,management consulting firm specializing in the pharmaceutical ... as one of the best,places to work in the ... Business Journal, ranking third among midsize companies. The award,was ... annual Best,Places to Work luncheon and awards ceremony on ...
Cached Biology Technology:Accera, Inc. Names William T. Poncy Vice President of Commercial Development 2Accera, Inc. Names William T. Poncy Vice President of Commercial Development 3MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Campbell Alliance Named 'Best Place to Work' by Triangle Business Journal 2
(Date:8/22/2014)... 2014 Diabetes affects nearly 10 percent of ... diabetics: constant finger pricking to test blood glucose ... reports the development of a protein that could ... for diabetes patients. In the American Chemical Society,s ... shows off her "designer protein" that could eventually ...
(Date:8/22/2014)... important discoveries in basic and clinical research and ... into a complex offensive spanning multiple fronts. , ... lab could help find new and more selective ... that targets a specific enzyme overexpressed in certain ... from brain tumours. , Chemistry professor Christopher Cairo ...
(Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... 2013) The world,s leading conservation organizations have joined together ... eastern lowland gorilla ( Gorilla beringei graueri ). Found ... Democratic Republic of Congo (DRC), Grauer,s gorilla is not only ... largest primate in the world. With their entire range ...
... advance toward overcoming a major barrier to tapping the ... medicine in developing new and more effective modern drugs. ... Information and Modeling . Andreas Bender and ... modern medicine. In the world,s largest international clinical trial, ...
... World, the first international conference examining the critical link ... the University of Pennsylvania from Wednesday, March 13, through ... Penn Institute for Urban Research (Penn IUR), in partnership ... Steering Committee representing nine schools and six centers, is ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3Penn conference tackles complex relationship between urbanization and food 2
... in two product models - the 5000AT+ and ... that the 6000AT+ includes a membrane desolvation unit ... improved detection limits and reduced oxides. The Ultrasonic ... elements by 10-40 times. Note that with ICP-MS ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Request Info...
... (patent pending) was developed using a protein engineering ... DNA binding pocket of wild-type DNase I. These ... for DNA. The result is a versatile enzyme ... and an ability to maintain at least 50% ...
Biology Products: